Cardiovascular System / Hypertension

Niperten 30s 10 mg film-coated tablets

Brands: KRKA-RUS/KRKA d.d. Novo Mesto (Russia)

$9.60

Quantity

Niperten 30s 10 mg film-coated tablets quantity

Add to cart

Add to wishlist

Sku:

43d1b4642558

Brands:: KRKA-RUS/KRKA d.d. Novo Mesto (Russia)

Description

The instruction for medical use

of NIPERTEN medicine

the Trade name

Niperten

Mezhdunarodnoye the unlicensed

name Bisoprolol Lekarstvennaya

the Tablet form, film coated 2.5 mg, 5 mg and 10 mg

Structure

One tablet contains

active agent – the bisoprolola fumarates (2: 1) 2.50 mg, 5.00 mg and 10.00 mg,

excipients: microcrystalline cellulose, sodium of starch glikolit, povidone, silicon dioxide colloidal anhydrous, magnesium stearate,

a film cover: gipromelloza, polyethyleneglycol, titan E 171 dioxide, talc.

The description

Oval biconvex tablets, film coated white color, with risky on one party and smooth on another (for a dosage of 2.5 mg).

Round biconvex tablets, film coated white color, with risky on one party and smooth on another (for dosages of 5 mg and 10 mg).

Pharmacotherapeutic group

– adrenoblockers selection.

The code of automatic telephone exchange C07AB07

the Pharmacological

Pharmacokinetics Later properties of intake absorption is 80 90%, meal does not influence absorption. The maximum concentration in blood plasma is observed in 13 h, communication with proteins of blood plasma about 30%. Permeability through a blood-brain barrier and a placental barrier low. The bioavailability is about 85 – 90% after intake, meal does not affect bioavailability. Concentration of a bisoprolol in blood plasma are proportional to the accepted dose in

the range from 5 mg to 20 mg.

50% of the accepted dose are metabolized in a liver with formation of inactive metabolites, elimination half-life (T1/2) 1012 hours. About 98% of a dose are removed by kidneys, less than 2% with bile are brought out of them 50% in not changed look.

Niperten’s pharmacodynamics – selection 1 adrenoblocker, without own sympathomimetic activity, does not possess membrane stabilizing action. Reduces activity of renin of blood plasma, reduces the need of a myocardium for oxygen, urezhat the heart rate (HR) (at rest and at loading). Niperten has hypotensive, antiarrhytmic and anti-anginal effect. Blocking 1 adrenoceptors of heart in low doses, Niperten reduces stimulated catecholamines formation of cyclic adenosinemonophosphate (tsAMF) from adenosine triphosphate (ATP), reduces intracellular current of calcium ions (Sa2+), renders negative hrono-, dromo-, batmo- and inotropic action, reduces atrioventricular conductivity and excitability.

When exceeding a therapeutic dose has 2-adrenoceptor blocking effect.

The general peripheric vascular resistance at the beginning of drug Niperten use, in the first 24 h, increases (as a result of reciprocal increase of activity – adrenoceptors and elimination of stimulation of 2 adrenoceptors), in 13 days returns to initial, and at prolonged use decreases.

The hypotensive effect is connected with reduction of minute volume of blood, sympathetic stimulation of peripheral vessels, recovery of sensitivity in response to a lowering of arterial pressure (ABP) and influence on the central nervous system (CNS). In arterial hypertensia the effect occurs in 25 days, stable action is noted through the 12th month.

The anti-anginal effect of the drug Niperten is caused by reduction of need of a myocardium for oxygen as a result of an urezheniye of frequency of warm reductions (ChSS) and decrease in contractility of a myocardium, lengthening of a diastole, improvement of perfusion of a myocardium. Due to increase in end diastolic pressure in a left ventricle and increases in stretching of muscle fibers of ventricles the need for oxygen, especially at patients with the chronic heart failure (CHF) can increase.

The antiarrhytmic effect of the drug Niperten is caused by elimination of aritmogenny factors (tachycardias, superactivity of sympathetic nervous system, the increased maintenance of tsAMF, arterial hypertension), reduction of speed of spontaneous excitement of sinus and ectopic pacemakers and delay of atrioventricular (AV) carrying out (mainly in antegrade and, to a lesser extent, in the retrograde direction through an AV node) and on additional ways.

At use in average therapeutic doses, unlike non-selective – adrenoblockers, Niperten has less significant impact on the bodies containing 2 adrenoceptors (pancreas, skeletal muscles, smooth muscles of peripheral arteries, bronchial tubes and a uterus) and on carbohydrate metabolism, does not cause a delay of ions of sodium (Na+) in an organism, the expressiveness of atherogenous action does not differ from effect of propranolol.

Indications

– arterial hypertension

– coronary heart disease: prevention of attacks of angina of exertion

– chronic heart failure

the Route of administration and doses

Inside, in the morning on an empty stomach, without chewing, once.

Arterial hypertension and coronary heart disease: prevention of attacks of angina of exertion

Is recommended to accept 5 mg once. If necessary the dose is increased to 10 mg of 1 times a day. Maximum daily dose of 20 mg.

Patients with a renal failure at the clearance of creatinine (CC) have less than 20 ml/min., or with the profound abnormal liver functions the maximum daily dose of 10 mg.

Dose adjustment is not required from elderly patients.

Chronic heart failure

the Initiation of treatment of chronic heart failure the drug Niperten demands obligatory carrying out the special period of selection dosed

Preliminary conditions to start therapy the following:

– HSN without signs of aggravation in the previous six weeks

– almost unchangeable basic therapy in the previous two weeks

– treatment by optimum doses of inhibitors of angiotensin-converting enzyme (APF) (and vasodilators, in case of intolerance of APF inhibitors), diuretics and, if necessary, cardiac glycosides

Treatment is appointed dosed according to the specified scheme of selection

the individual reaction of the patient to the appointed therapy, i.e. a dose Is possible it is possible to increase only if the previous dose was well transferred.

1ya week: 1.25 mg (1/2 tablets on 2.5 mg) once a day

2 I week: 2.5 mg once a day

3 I week: 3.75 mg once a day

4 I 7 I week: 5 mg once a day

8 I 11 I week: 7.5 mg once a day

12 I week and further: 10 mg once a day as maintenance therapy

the Maximum recommended dose of the drug Niperten makes 10 mg once a day.

After an initiation of treatment drug in a dose of 1.25 mg (1/2 tablets of 2.5 mg) of the patient it is necessary to observe within about 4 hours (control of ChSS, the ABP, disturbance of conductivity on the ECG, signs of deterioration in chronic heart failure).

During the period of selection of doses or after it there can be a temporary deterioration in a course of HSN, a liquid delay in an organism, arterial hypotension or bradycardia. In this case it is recommended to pay, first of all, attention to selection of a dose of the accompanying basic therapy (to optimize a dose of diuretic and/or APF inhibitor), before a drug Niperten dose decline. Drug treatment should be interrupted only in urgent cases.

After stabilization of a condition of the patient it is necessary to carry out repeated titration, or to continue treatment.

Treatment duration for all indications

Therapy by the drug Niperten usually is long.

Side effects

Very often (& ge, 1/10):

– sinus bradycardia

– a withdrawal (strengthening of attacks of stenocardia, increase in the ABP)

it is frequent (& ge, 1/100 to & lt, 1/10):

– disturbance of conductivity of a myocardium, easing of contractility of a myocardium,

– dizziness, a headache

– dryness of a mucous membrane of an oral cavity, change of taste, nausea,

vomiting, an abdominal pain, a constipation or diarrhea

– manifestation of a vasomotor spasm (strengthening of disturbance of peripheric

circulation, a cold snap of the lower extremities, Reynaud’s syndrome)

– an asthenia, increased fatigue

Infrequently (& ge, 1/1000 to & lt, 1/100):

– disturbance of atrioventricular conductivity, heartbeat, arrhythmias,

development (aggravation) of HSN (puffiness of anklebones, feet, an asthma), sni-

zheny ABP

– congestion of a nose, difficulty of breath when assigning in high

doses (loss of selectivity) and/or at predisposed patients

laringo- and a bronchospasm

– a myasthenia, a tremor, spasms (including gastrocnemius muscles)

– orthostatic hypotension

– sleep disorders, a depression

Seldom (& ge, 1/10,000 to & lt, 1/1,000):

– the concern, confusion of consciousness or short-term loss of memory,

a hallucination

– a disorder of vision, reduction of secretion of plaintive liquid, dryness and

morbidity of eyes (it is necessary to consider when carrying

contact lenses by the patient)

– allergic reactions (rhinitis, a skin itching, rash, a small tortoiseshell)

– change of activity of enzymes of a liver (increase in ALT, nuclear heating plant, beat

a ruby, triglycerides)

– abnormal liver functions (dark urine, yellowness of scleras or skin,

a cholestasia)

– a hyperglycemia (at patients with non-insulin-dependent diabetes),

a hypoglycemia (at the patients receiving insulin), a hypothyroid

state

– sweating strengthening, a dermahemia

– weakening of a libido, decrease in potency,

Is very rare (& lt, 1/10,000):

– paresthesias in extremities (at patients with the alternating lameness and

Reynaud’s syndrome),

– a stethalgia

– conjunctivitis

– a dieback, psoriazopodobny skin reactions, aggravation of symptoms

of psoriasis, an alopecia

– thrombocytopenia (unusual bleedings and hemorrhages),

an agranulocytosis, a leukopenia

– a pre-natal growth inhibition, a hypoglycemia, bradycardia.

– a dorsodynia,

the Contraindication arthralgia

– hypersensitivity to a bisoprolol to a fumarat, others – adrenoblockers and other components of drug

– shock (including cardiogenic)

– collapse

– a fluid lungs

– acute warm insufficiency

– chronic heart failure in a decompensation stage

– atrioventricular (AV) blockade of II III degrees

– sinuatrial blockade

– a sick sinus syndrome

– the profound bradycardia (ChSS less than 50 beats/min)

– Printsmetal’s stenocardia

– a cardiomegaly (without symptoms of heart failure)

– arterial hypotension (systolic arterial blood pressure up to 100 mm rt. St., especially in a myocardial infarction)

– severe forms of bronchial asthma and the chronic obstructive pulmonary disease (COPD) in the anamnesis

– a concomitant use of inhibitors of a monoaminooxidase (MAO) (except for MAO-B)

– late stages of disturbance of peripheric circulation

– a Raynaud’s disease

– a pheochromocytoma (without simultaneous use – adrenoblockers)

– a metabolic acidosis

– children’s and teenage age up to 18 years (the efficiency and safety are not established)

Medicinal interactions

the Allergens used for an immunotherapy, or extracts of allergens for skin tests increase risk of emergence of heavy system allergic reactions or an anaphylaxis at the patients receiving bisoprolol.

Yodosoderzhashchy X-ray contrast intravenous agents increase risk of development of anaphylactic reactions.

Phenytoinum at intravenous administration, means for inhalation anesthesia (derivatives of hydrocarbons) increase expressiveness of cardiodepressive action and probability of decrease in the ABP.

Changes efficiency of insulin and hypoglycemic means for intake, masks symptoms of the developing hypoglycemia (tachycardia, increase in the ABP).

Reduces clearance of lidocaine and xanthines (except theophylline) and increases their concentration in blood plasma, especially at patients with initially increased clearance of theophylline under the influence of smoking.

Hypotensive effect non-steroidal anti-inflammatory drugs (NPVP) (a delay of ions of sodium (Na+) and blockade of synthesis of prostaglandin kidneys) weaken, glucocorticosteroids and estrogen (delay of ions of Na+).

Cardiac glycosides, Methyldopum, reserpine and guanfatsin, blockers of slow calcium channels (verapamil, diltiazem), Amiodaronum and other antiarrhytmic means increase risk of development or aggravation of bradycardia, AV of blockade, cardiac arrest and heart failure.

Nifedipine can lead to considerable decrease in the ABP.

Diuretics, a clonidine, sympatholytics, gidralazin and other antihypertensives can lead to excessive decrease in the ABP.

Extends action of not depolarizing muscle relaxants and increases anticoagulating effect of coumarins.

Rub – and tetracyclic antidepressants, antipsychotic means (neuroleptics), ethanol, sedative and somnolent medicines strengthen oppression of central nervous system.

Simultaneous use with MAO inhibitors, owing to considerable strengthening of hypotensive action is not recommended, having rummaged in treatment between intake of MAO inhibitors and a bisoprolola has to make not less than 14 days.

Not hydrogenated alkaloids of an ergot increase risk of development of disturbances of peripheric circulation.

Ergotamine increases risk of development of disturbance of peripheric circulation, Sulfasalazinum increases concentration of a bisoprolol in blood plasma, rifampicin reduces T1/2.

Special instructions

do not interrupt treatment sharply and do not change the recommended dosage without preliminary consultation with the doctor as it can lead to temporary deterioration in action of the heart. Treatment should not be interrupted suddenly, especially at patients with coronary heart disease. If the termination of treatment is necessary, then the dosage should be reduced gradually.

Control of the patients taking the drug Niperten has to include measurement of ChSS and the ABP (in an initiation of treatment daily, then 1 time in 34 months), carrying out the ECG, determination of level of glucose in blood at patients with diabetes (1 time in 45 months). At elderly patients it is recommended to monitor function of kidneys (1 time in 45 months).

It is necessary to train the patient in a technique of calculation of ChSS and to instruct about need of medical consultation at ChSS less than 50 ud. / min.

Before an initiation of treatment it is recommended to conduct a research of function of external respiration at patients with the burdened bronchopulmonary anamnesis.

Approximately at 20% of patients with stenocardia – adrenoblockers are inefficient. Basic reasons: the profound coronary atherosclerosis with a low threshold of ischemia (ChSS less than 100 ud. / min.) and the increased final diastolic volume of a left ventricle breaking a subendocardial blood stream.

Smokers have an efficiency – adrenoblockers lower.

The patients using contact lenses have to consider that against the background of treatment the reduction of products of plaintive liquid is possible.

When using the patients with a pheochromocytoma have a risk of developing paradoxical arterial hypertension (if effective – an adrenoblokada is previously not reached).

In a thyrotoxicosis Niperten can disguise certain clinical signs of a thyrotoxicosis (for example, tachycardia). Sharp cancellation at patients with a thyrotoxicosis is contraindicated as it is capable to strengthen symptomatology.

In diabetes Niperten can mask the tachycardia caused by a hypoglycemia. Unlike non-selective – adrenoblockers practically does not strengthen the hypoglycemia caused by insulin and does not delay restoration of concentration of glucose in blood to normal level.

At a concomitant use of a clonidine its reception can be stopped only in several days after drug withdrawal Niperten.

Strengthening of expressiveness of hypersensitivity reaction and lack of effect of usual doses of epinephrine against the background of the burdened allergological anamnesis is possible.

In case of need performing planned surgical treatment carry out drug withdrawal for 48 h prior to the beginning of the general anesthesia. If the patient Niperten before surgical intervention accepted, it should pick up medicine for the general anesthesia with minimum negative inotropic effect.

Reciprocal activation of vagus nerve can be eliminated with intravenous administration of atropine (12 mg).

The medicines reducing stocks of catecholamines (including reserpine), can strengthen action – adrenoblockers therefore the patients accepting such combinations of medicines have to be under constant observation of the doctor regarding identification of the significant lowering of the ABP or bradycardia.

Patients with bronkhospastichesky diseases can appoint cardioselective – adrenoblockers in case of intolerance and/or inefficiency of other antihypertensives. The overdose is dangerous by development of a bronchospasm.

In case of identification at patients of advanced age of the accruing bradycardia (less than 50 ud. / min.), the significant lowering of the ABP (systolic arterial blood pressure is lower than 100 mm Hg.), blockade AV, it is necessary to reduce a dose or to stop treatment.

It is recommended to stop therapy by the drug Niperten at development of a depression.

It is impossible to interrupt sharply treatment because of danger of development of a withdrawal (heavy arrhythmias and a myocardial infarction). Cancellation is carried out gradually, reducing a dose within 2 weeks and more (lower a dose by 25% in 3-4 days). It is necessary to cancel before a research of content in blood and urine of catecholamines, a normetanefrin and vanilinmindalny acid, credits of antinuclear antibodies.

With care: a liver failure, chronic kidney disease, a myasthenia, a thyrotoxicosis, diabetes, AV blockade of the I degree, a depression (including in the anamnesis), psoriasis, allergic reactions (in the anamnesis), advanced age.

Pregnancies and the period of a lactation

it is possible in case the advantage for mother exceeds risk of development of side effects at a fruit and the child.

As a rule, beta blockers reduce a blood stream in a placenta and can influence fetation. It is necessary to trace attentively a blood stream in a placenta and a uterus and also to monitor growth and development of future child, and in case of dangerous manifestations concerning pregnancy or a fruit, to take alternative therapeutic measures.

It is necessary to examine carefully the newborn after the delivery. In the first three days of life there can be symptoms of decrease in level of glucose in blood and ChSS.

There are no data on excretion of a bisoprolol in breast milk or safety of impact of a bisoprolol on babies. Therefore administration of drug Niperten is not recommended to women during feeding by a breast.

Features of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms

the Question of a possibility of occupations potentially dangerous types of activity requiring special attention and speed of psychomotor reactions should be solved only after assessment of individual reaction of the patient to drug (especially in an initiation of treatment, in connection with a possibility of development of dizziness).

Overdose

Symptoms: arrhythmia, ventricular premature ventricular contraction, profound bradycardia, AV blockade, significant decrease in the ABP, HSN, cyanosis of nails of fingers or palms, breath difficulty, bronchospasm, dizziness, unconscious states, spasms.

Treatment: gastric lavage and purpose of the adsorbing means, symptomatic therapy: at the developed AV to blockade intravenous administration of 12 mg of atropine, epinephrine or temporary statement of a pacemaker, in ventricular premature ventricular contraction lidocaine (the drugs IA of a class are not used), at decrease in the ABP in the patient has to be in position of Trendelenburg if there are no symptoms of a fluid lungs intravenous administration of plasma substituting solutions, at inefficiency the administration of epinephrine, a dopamine, Dobutaminum (for maintenance of chronotropic and inotropic action and elimination of the significant decrease in the ABP), in heart failure cardiac glycosides, diuretics, a glucagon, in spasms intravenously diazepam, at a bronchospasm 2-adrenostimulyator is inhalation.

A form of release and packing

On 10 tablets in blister strip packaging from a film of polyvinylchloride and aluminum foil.

On the 3rd blister strip packagings together with the instruction for use in the state and Russian languages place in a pack from cardboard.

To Store storage conditions at

a temperature not higher than 30 S. Hranit out of children’s reach!

A period of storage

2 years

not to apply after the storage expiration

Prescription status

According to the prescription

LLC KRKA-RUS Producer,

Russia Moskovskaya St., 50, 143500, Istra, the Moscow region, Russia

the Owner of the registration certificate

of KRK, of, the Place, Slovenia

the Address of the organization accepting in the territory of the Republic of Kazakhstan claims from consumers on quality of products (goods)

Representation of KRK, of Is new. The place in PK

PK is new, 050059, Almaty, Al-Farabi Ave., 5/1, section 3 A, the 4th floor

ph.: +7 (727) 311 08 09

fax: +7 (727) 311 08 12

www.krka.si

to Develop

Additional information